Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence From Thai Acute Myeloid Leukemia Registry-Reference-Cited by-同舟云学术

Comparison of Three Doses of Cytarabine Consolidation for Intermediate- and Adverse-risk Acute Myeloid Leukemia: Real World Evidence From Thai Acute Myeloid Leukemia Registry

Published:2022-10 Issue:10 Volume:22 Page:e915-e921
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Chanswangphuwana Chantiya^ORCID,Polprasert Chantana^ORCID,Owattanapanich Weerapat,Kungwankiattichai Smith,Rattarittamrong Ekarat,Rattanathammethee Thanawat^ORCID,Limvorapitak Wasithep^ORCID,Saengboon Supawee,Niparuck Pimjai,Puavilai Teeraya,Julamanee Jakrawadee,Saelue Pirun,Wanitpongpun Chinadol,Nakhakes Chajchawan,Prayongratana Kannadit,Sriswasdi Chantrapa

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference23 articles.

1. Acute myeloid leukemia;Döhner;N Engl J Med,2015

2. Acute myeloid leukaemia and related precursor neoplasm;Arber,2017

3. Intensive postremission chemotherapy in adults with acute myeloid leukemia;Mayer;N Engl J Med,1994

4. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia;Löwenberg;Blood,2013

5. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial;Schaich;J Clin Oncol,2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medium-cumulative dose of cytarabine in consolidation therapy shows the greatest benefit in AML patients;Holistic Integrative Oncology;2024-05-21

2. Single dose of peg GCSF compared with daily GCSF in de novo acute myeloid leukemia patients on high dose cytarabine consolidation chemotherapy (HIDAC);2024-01-05

3. Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1;International Journal of Hematology;2022-08-28